Understanding how lung cancer adapts to new therapies
Mechanisms of adaptation and resistance to emerging therapies for lung cancer
This study is looking at how lung cancer cells change and become resistant to new treatments, especially for those with a specific KRAS mutation, to help find better ways to treat patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11065478 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which lung cancer cells adapt and develop resistance to emerging therapies, particularly those targeting the KRAS G12C mutation. By studying the biological processes involved, the research aims to identify factors that influence treatment effectiveness and resistance. Patients with lung cancer, especially those with KRAS mutations, may benefit from insights gained through this research, which could lead to improved therapeutic strategies. The approach includes analyzing cancer cell behavior and responses to specific inhibitors that have shown promise in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung cancer who have KRAS G12C mutations.
Not a fit: Patients with lung cancer who do not have KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients with KRAS mutations, potentially improving survival rates.
How similar studies have performed: Other research has shown success in targeting KRAS mutations, particularly with the development of specific inhibitors like sotorasib, indicating a promising avenue for further exploration.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Lito, Piro — Sloan-Kettering Inst Can Research
- Study coordinator: Lito, Piro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.